BioVersys AG (CHIX:BIOVZ) FFO


CHIX:BIOVZ BioVersys AG CHIX:BIOVZ
14 GF Score
Price CHF27.10
View Full Analysis

What is BioVersys AG FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:BIOVZ
14GF Score
BioVersys AG CHIX:BIOVZ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Business Description

Other Exchanges W33:GermanyBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
14GF Score

Get the complete analysis for CHIX:BIOVZ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.10
Price